PFE Stock Pfizer Inc - Complete Overview
Nyse / Pharmaceutical Products / Healthcare / PFE Stock
|Avg Daily Volume||24.25M|
PFIZER INC (PFE) OVERVIEW
PFE stock is a pharmaceutical products company traded on Nyse. It is valued at 212.76B US dollars. There are 5.95B shares outstanding which Pfizer Inc issued to investors. Volatility of the stock is LOW, and the daily volume is 16.00% stock on average. Pfizer Inc is paying dividends with the latest yield of 3.60%. It brought investors a total return of 12.49% over the last 12 months. Pfizer Inc stock is relatively cheap. It's P/E ratio is below the market average.
Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE)
Which stock wins in a match-up between these huge drugmakers?
3 Drugs That Are Moving the Needle at Johnson & Johnson
Johnson & Johnson owes a lot of its early success this year to rapidly growing sales of three key products.
Danger Zone: Fund Managers That Don't Analyze Details In 10-Ks
Investing in a company without thoroughly analyzing all of its 10-Ks and 10-Qs is like hiking in unfamiliar terrain without a map or GPS. The more important task for responsible investors is thoroughl
Pfizer's DMD Drug Could Spell Long Term Trouble For Sarepta
Pfizer’s new DMD drug is entering the clinic and its mechanism of action is much simpler than Sarepta’s Exondys 51.It is also more broadly applicable to all forms of DMD, whereas eteplirsen is only ap
Merck leads Dow industrials higher
Shares of Merck & Co. rose on Monday, providing an outsize boost to the Dow Jones Industrial Average in early trading. The stock rose 2.4%, by far the biggest gainer among the blue-chip average's 30 components. The rally came after it released late-stage results showing that a cancer drug combination using its Keytruda reduced patients' risk of death by half, a significant improvement. Health-care stocks were the top-performing sector of the day, and among other components, Johnson & Johnson was up 1.5% and Pfizer Inc. rose 0.7%. The Dow rose 0.6% while the S&P 500 was up 0.5% and the Nasdaq Composite Index rose 0.4%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
How Will This Unexpected War For First-Line Lung End?
Upcoming approvals of two newer EGFR inhibitors will create a high stakes game in first-line lung cancer.The picture of dominance for osimertinib may not be as clear as it seems.Pfizer has a good chan
|Price to Earnings||10.01||67.64||84.09||30.67|
|Price to Book Value||2.98||3.93||4.63||3.52|
|Price to Sales||4.05||3.57||4.30||3.34|
|Return on Equity||34.20%||16.58%||22.79%||15.18%|
|Return on Assets||12.50%||4.83%||6.75%||5.64%|